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1. Introduction 
1.1 Role of vaccines in disease prevention and cancer prevention 
Vaccine therapy is traditionally designed to be given prophylactically in order to prevent 
infectious diseases. Vaccines formulated against pathogens known to cause disease have 
been successfully created and implementation policies have been effective in the prevention 
and eradication of many life-threatening diseases. A well-know example of the success that 
is possible with a well constructed vaccine and an efficient vaccination strategy is the 
poliomyelitis vaccine. Poliomyelitis was first documented in the late 19th century and it 
quickly reached the level of causing annual global endemics. The vaccine was introduced in 
the United States in 1955 and was associated with an immediate reduction in the disease and 
eventual the elimination of wild-type polioviruses in the United States by 1972. Subsequent 
global expansion of polio vaccination has resulted in a drastic reduction of documented 
cases of the disease as well as eradication of wild type 2 poliovirus [1].  
A natural next step after the development of prophylactic vaccines to prevent infectious 
disease was the emergence of vaccines used against specific infectious agents that are 
known to cause cancer. An estimated 12% of human cancers are attributable to viral 
infections [2]. Viral infections that are known to cause cancer include human papillomavirus 
(HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), and 
Kaposi’s sarcoma-associated herpes virus (KSHV). Safe and effective vaccines have been 
developed against two oncovirus, HPV to prevent HPV-associated cervical carcinoma and 
HBV to prevent HBV-associated hepatocellular carcinoma.  
1.2 Primary versus secondary prevention 
A small number of cancers are directly associated with exposure to an oncovirus. 
Vaccinating against these viruses and preventing infection and subsequent cancer formation 
is referred to as ‘primary cancer prevention’. This term also encompasses the theoretic 
potential of vaccinating against non-infectious cancers prior to tumorigenesis. Most cancers 
do not have a direct link to one specific pathogen. Therefore, experimental cancer vaccines 
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are designed to stimulate an immune response against pathogens from established tumors. 
The creation of a vaccine against an established tumor, either invasive or pre-invasive, is 
referred to as ‘secondary cancer prevention’. The goal of secondary cancer prevention is to 
use active specific immunotherapy to eradicate cancer cells without causing harm to healthy 
tissues. Successful secondary cancer prevention can have of a number of goals including 
inhibiting the evolution of pre-invasive to invasive disease, impeding the progression of 
disease and the formation of metastases, and increasing patient survival.  
1.3 Breast cancer background and potential for vaccine therapy 
Breast cancer remains the most common non-skin cancer diagnosis and the second leading 
cause of cancer related death in women [3]. Major improvements in the surgical and 
adjuvant treatment of breast cancer during recent decades have resulted in improved 
disease-free and overall survival for breast cancer patients. Morbidity from surgery, 
chemotherapy and radiation is substantial and even with optimal current treatments 
approximately 40,000 women a year succumb to breast cancer [3].  
A general challenge to constructing an effective cancer vaccine is that all tumor cells contain 
self-antigens that vary from normal tissue by mutation or expression level and therefore 
cancer cells are able to evade immune surveillance. It is essential to find tissue and tumor 
specific molecules that are capable of stimulating an immune response. Vaccination efforts 
are often focused on high risk cancers where the clinical impact can be the greatest. 
Immunotherapy, which involves actively manipulating the immune system to target 
tumors, promises the potential for a safe and effective adjuvant treatment for patients with 
high risk breast cancer. 
1.4 Molecular phenotypes of breast cancer  
Elucidation of the molecular basis of carcinogenesis has identified that breast cancer and 
probably all solid tumors exist as discrete molecular subtypes rather than a single disease. 
Breast cancer is a heterogeneous disease and several microarray profiling studies have 
identified distinct subtypes of breast tumors that are associated with different clinical 
outcomes [4-7]. The implications of classifying tumors based on gene profiling are both 
therapeutic and predictive. Gene expression profiling facilitates both  the prediction of patient 
outcome and the selection of patients that will benefit from specific adjuvant therapies.  
Breast tumors are typically classified into five distinct genetic subtypes based on 
immunphenotype and the expression of the following receptors; estrogen (ER), 
progesterone (PR), human epidermal growth factor receptor-2/neu (HER-2), cytokeratin 5/6 
(CK5/6) and epidermal growth factor (EGFR). Luminal A cancers are ER positive and/or PR 
positive, HER-2 negative and Grades 1 or 2. Luminal B cancers are (a) ER positive and/or PR 
positive and HER-2 positive or (b) ER positive and/or PR positive and HER-2 negative and 
high grade. HER-2 type cancers stain negative for ER and PR and positive for HER-2. Basal-
like tumors have no staining for ER, PR and HER-2, but do stain positive for CK 5/6 and/or 
EGFR. Tumors that have no staining for all 5 markers are referred to as Unclassified [4, 8, 9]. 
These molecular phenotypes of breast carcinoma can be delineated with routine 
immunohistochemical markers. Substantial differences in the survival of patients with 
different subtypes have been reported. Luminal A tumors have a significantly better 5- and 
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10- year survival compared to Luminal B, HER-2, Basal-like and unclassified tumors [4]. In 
addition, certain ductal carcinoma in situ (DCIS) lesions over express HER-2, which results 
in a more rapid progression to invasive disease [11] and higher risk of recurrence [10, 13].  
Anti-estrogen therapy is used for primary and secondary prevention of luminal tumors, but 
there are currently no similar options for prevention of the high risk tumors (Luminal B, 
Basal, HER-2). Trastuzumab is a human epidermal HER-2-targeted monoclonal antibody 
that has been shown to decrease recurrence and improve survival when used in the 
adjuvant setting combined with chemotherapy to treat patients with invasive disease that 
over-express the HER-2 protein [14]. The effect of trastuzumab has been postulated to be 
mediated by antibody-dependent cytotoxicity (ADCC) [15]. Unfortunately, this regimen is 
often not curative [14, 16] and patients can become resistant to therapy and ultimately fail 
[17] . A protein in the HER family would be an ideal target for a breast cancer vaccine. The 
HER family of tyrosine receptor kinases of which HER-1, HER-2, HER-3 and HER-4 are 
members make intriguing targets as these molecules are implicated in HER-2 and Basal-type 
breast cancers and also play a significant role in the development of some of the Luminal-
type breast cancers. 
2. Cancer and the immune response 
The immune system is a complex and overlapping cellular network that protects against 
foreign pathogens and closely regulates self-tolerance. The innate system represents the first 
line of defense to tissue injury and foreign pathogens. It is comprised of natural barriers, 
cytokines, neutrophils, macrophages, dendritic cells (DCs), and natural killer (NK) cells [18, 
19]. The innate response also includes the activation of the complement pathway. The early, 
antigen-nonspecific response of the innate immune system is necessary for the activation of 
the adaptive immune system which is comprised of B- and T- lymphocytes that express 
antigen-specific receptors and are ultimately responsible for producing and maintaining 
immunologic memory [20].  
2.1 Cancer response to the immune system: exploitation and evasion and editing 
In order for cancer cells to survive they must be able to either evade the immune system or 
to exploit it in a way that causes immune cells to actually enhance tumor growth. The 
immune response to neoplastic development is often described as paralleling the body’s 
response to inflammation. It can be simplistically divided into an ‘acute’ and ‘chronic’ 
reaction. Epithelial cancer progression and eradication, similar to an inflammatory reaction, 
are regulated by both the innate and adaptive immune systems [21]. The specific immune 
cells involved paradoxically enhance and eliminate carcinogenesis. Accumulated data from 
animal and human studies has shown that the acute immune response to tumor growth is 
an anti-neoplastic process, comprised of CD8+ T cells, TH1 cells and NK cells [22]. 
Continued epithelial cancer development leads to dysregulation between the two subsets of 
the immune system and excessive activation results in an immune response that is similar to 
the body’s response to chronic inflammation. Chronic activation of innate immune cells is 
associated with an ongoing infiltration cells that facilitate the survival of neoplastic cell 
survival by stimulating angiogenesis, inflammation and proliferation [19-23]. The chronic 
activation of the innate immune system also directly contributes to cancer development by 
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suppressing the anti-tumor adaptive immune response (CD8+ T cells, TH1 cells, NK cells) 
and allowing tumor cells to escape from surveillance. One type of innate immune cells, 
myeloid suppressor cells, are known to accumulate in the peripheral blood of patients with 
cancer [24, 25]. Myeloid suppressor cells directly inhibit T lymphocytes and therefore inhibit 
the anti-tumor environment produced by innate immune cells [25, 26]. These cells also 
promote tumor growth by assisting in angiogenesis [27].  
In addition to suppressing the anti-tumor effects of the adaptive immune system, chronic 
activation of the cells of the innate immune (B cells, TH2 cells) response actually promotes 
tumor development [21]. Multiple population based studies have definitively linked chronic 
inflammatory conditions with the development of certain cancers. For example Helibacter 
pylori infection and gastric cancer, inflammatory bowel disease and colon cancer, and 
hepatitis and hepatocellular carcinoma [28-30]. Subsequent studies that revealed an inverse 
relationship between long-term usage of anti-inflammatory medications and a decreased 
cancer risk support the support the direct association between chronic inflammation and 
cancer development [31]. Through a variety of cellular mediators, chemokines and 
cytokines, innate immune cells and TH2 cells are able to create a pro-tumor 
microenvironment that favors cell proliferation, genomic instability and malignant 
conversion [32].  
In addition to exploiting the immune system to stimulate tumor growth, cancer cells must 
also be able to evade the immune response. Prolonged activation of the innate immune cells 
results in subsequent suppression of the anti-tumor adaptive immune response, therefore 
allowing tumors cells to avoid specific immune surveillance. Neoplastic lesions attract 
regulatory T cells that suppress cytotoxic T cells [33]. Furthermore, cancer cells avoid 
immune surveillance by over expression or mutation of self-peptides. These non-foreign 
antigens are only weakly immunogenic and thus evade the host immune response or do not 
induce an immune specific response in the same way that a completely foreign antigen 
would.  
Growing tumors are phenotypically sculpted by the immune system. One of the risks of 
cancer immunotherapy is that it can result in ‘immunoediting’, whereby the immune 
response sculpts cancer cells into a more aggressive phenotype [34, 35]. Surviving tumor 
cells acquire the ability to evade immune recognition through selective pressures that favor 
the survival and reproduction of cancer cells that lack the selected antigen. In considering an 
immunotherapy target it is important to select an antigen that is central to the survival of the 
tumor cell or that contributes to the aggressiveness of the disease. Therefore, when the cells 
adapt, only variants that do not express the antigen will survive. This creates a tumor that 
consists of cells that are unable to survive or that have a phenotype that is associated with a 
better clinical prognosis [36]. This process of immunoediting explains in part why targeting 
only single antigens has resulted in limited clinical success.  
2.2 General potential for vaccine therapy 
The intimate relationship between cancer and the immune system illustrates the potential 
for an effective immunotherapeutic agent, such as a cancer vaccine, to harness the immune 
system and then to manipulate the immune cells to create a strong anti-tumor environment. 
Traditional vaccines are designed to be prophylactic. The immunogens in the vaccines are 
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administered prior to disease exposure and effective immunity is created before infection. In 
contrast, cancer vaccines are intended to stimulate active immunity only after tumors cells 
are already present and established. Oftentimes, vaccines are not given until the cancer has 
spread systemically. Also, unlike bacteria or other microbes for which vaccines are used, all 
tumor cells also express antigens that are very similar to established self-antigens. The ideal 
vaccine target would be an antigen that is present only on cancer cells and not on normal 
cells. Since this is uncommon, one of the largest challenges in vaccine development is 
breaking immune tolerance without inducing autoimmune reaction that would be harmful 
to healthy tissues. Several vaccine approaches have been established for a multitude of 
cancers in both early and late stages.  
3. Immune response in relation to invasive and in situ breast cancer 
Breast cancer, both the in situ and invasive forms, is an ideal target for vaccine therapy since 
this disease creates a significant public health burden. There is potential for vaccines to 
inhibit the progression of in situ disease into invasive cancer. The ultimate goal would be to 
prevent the formation of breast cancer altogether. Central to success of using 
immunotherapy to treat breast cancer is that breast tumors have already been established to 
be relatively immunogenic and the growing tumors are subject to immunosurveillance. 
Tumor antigens that are over-expressed or mutated in breast cancer cells initiate the 
development of a tumor-specific adaptive immune response [23, 37, 38]. T-cells that 
recognize these antigens have been isolated from breast cancer patients [39, 40]. As further 
evidence that the cell-mediated immune reaction has an important role in breast cancer 
development and clinical outcome, lymphocyte infiltration has been shown to be associated 
with improved survival in breast cancer patients [41]. Recent data by Mahmoud et al 
confirmed that the presence of an efficient T-cell-mediated immune response is associated 
with breast cancer outcomes [42]. This study, a retrospective review of 
immunohistochemical staining from nearly 2000 patients with invasive breast cancer who 
received standard surgical and adjuvant treatment revealed that a higher number of CD8+ T 
lymphocytes infiltrating the tumor of adjacent stroma was independently associated with 
longer survival in patients with invasive breast cancers.  
In addition to being immunogenic, other aspects of breast cancer make it a good model for 
the development of a high-impact cancer vaccine, especially for patients with early stage 
disease. First, solid tumor cancer vaccines have had limited success when used to treat 
advanced or metastatic disease [43]. Breast cancer is most frequently treated with surgery 
and radiation therapy, which greatly decreases the disease burden, even in advanced cases. 
This tumor debulking provides a greater potential for disease eradication by competent 
immune cells. Second, the typical slow growing nature of most breast cancers allows for the 
expansion of immune cells over time with repeated vaccine boosters. Therefore, effective 
levels of active and immune competent cells can be achieved before the disease becomes 
systemic. 
Although most cancer vaccines have been developed to treat metastatic and systemic 
disease, there are a number of theoretical benefits to instead delivering vaccine therapy to 
patients with limited, microscopic cancer burden (as neoadjuvant therapy) in the absence of 
bulky disease. For instance, immune-competent patients would be able to produce a 
significant response comprised of antigen-competent T-cells that can rapidly expand when 
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presented with low antigen levels of early disease or early recurrence [44]. In addition, 
patients with early stage breast cancer do not require aggressive adjuvant therapy. The 
immune response in vaccinated patients with early stage cancers will not be compromised 
by the limitations of these cytotoxic treatments, most importantly the long-term reductions 
in functioning B and T lymphocytes [45-47]. There has therefore been a shift in the field of 
immunotherapy towards the treatment of patients with minimal disease and the prevention 
breast cancer formation. 
3.1 Immunotherapy and ductal carcinoma in situ  
With the increasing use of screening mammography, DCIS, the pre-invasive form of breast 
cancer, has become the most frequently diagnosed breast malignancy. DCIS is a 
heterogeneous disease both in terms of nuclear grade and expression of cell-surface 
receptors. DCIS is the non-obligate precursor of invasive ductal carcinoma. Low-grade DCIS 
may develop into invasive cancer slowly or not all. In contrast, high-grade DCIS almost 
always develops into invasive disease and often requires more aggressive surgical and 
adjuvant therapy [48].  
Currently, in most clinical practices, DCIS lesions are examined for the over-expression of 
ER and PR. Interest in the correlation between the molecular biology of DCIS and its clinical 
aggressiveness has led to staining for other markers. The additional information about 
potential antigen targets on DCIS is useful to guide development of novel adjuvant vaccines 
against DCIS. Specifically, for the past 6 years we have routinely stained all of the tumors 
from our DCIS patients for the over-expression of HER-2. Other biologic markers that are 
may have prognostic significance include HER 1-4, Ki67, p21, bcl-2, p16 and COX-2, c-myc 
and survivin [10, 13, 49]. 
Multiple recent studies have concentrated on determining molecular phenotypes for DCIS 
similar to those described for invasive breast cancer. In 2010 Tamimi et al published a large 
case series of DCIS and invasive breast tumors that were analyzed using tissue microarray 
and immunostaining for ER, PR, HER-2, CK 5/6 and EGFR. The authors concluded that the 
same 5 molecular phenotypes used to describe invasive cancer were all identified among the 
cases of DCIS. The prevalence of the lesions was not consistent between the DCIS and 
invasive tumors; the Luminal A phenotype was significantly more frequent among the 
invasive cancers and the Luminal B and HER-2 molecular phenotypes were more frequent 
in DCIS. The triple negative (Basal-like) phenotype is very uncommon in DCIS [50]. This is 
consistent with other studies that show a higher prevalence of HER-2 over expression in 
DCIS compared to invasive breast cancer [51-53]. Additional work has expanded the 
traditional molecular profiling to incorporate many more biomarkers that have been found 
to be biologically relevant to invasive breast cancer, including p53, bcl-2 and P-cadherin. Bcl-
2 was found to be one of the most common genes to be up regulated in the well-
differentiated sample of DCIS [53] and has also been reported to be a predictor of good 
prognosis in invasive breast cancers [54].  
DCIS is a particularly attractive vaccine target because the elimination of this disease 
prevents the subsequent development of invasive breast cancer. In addition, a novel 
neoadjuvant vaccine would be ideal to reduce size of these lesions prior to surgery. This 
could theoretically decrease the amount of breast tissue required to obtain clear margins 
www.intechopen.com
Targeting Molecular Pathways  
for Prevention of High Risk Breast Cancer: A Model for Cancer Prevention  
 
137 
during surgical excision and could also prevent the risk of subsequent recurrence. In 
general, DCIS patients are often otherwise healthy and are therefore able to mount an 
immune response to vaccination. The long latency period between the diagnosis of in situ 
disease and the development of invasive breast cancer, as well as the minimal disease 
burden of DCIS, provides an ideal therapeutic window to administer preventative vaccines. 
This strategy of treating early disease is applicable to early invasive breast cancer as well as 
to other cancers with indolent courses or those that are diagnosed in early stages, such as 
prostate and colon cancers, chronic leukemia and lymphomas [48, 55].  
4. Selection of a tumor antigen target  
The selection of an appropriate target tumor antigen is paramount to the success of any 
cancer vaccine. The ideal vaccine would stimulate a significant immune response without 
causing autoimmunity and without a detrimental side effect profile. One strategy to avoid 
autoimmunity and to enhance the specificity of the vaccine is to target tumor antigens that 
are overexpressed in cancer cells but have minimal expression in normal cells. As 
mentioned in a previous section, one challenge to targeting oncogenic molecules is that 
these tumor associated antigens are usually only weakly immunogenic and are therefore 
capable of evading the immune response, or the immune system can immunoedit the 
tumors leaving behind antigen negative tumor cells. Many of the breast cancer tumor 
antigens are also overexpressed in other cancers of epithelial cell origin (colon cancer and 
ovarian cancer). Previously targeted peptides in the experimental production of vaccines 
against breast cancer include Mucin (MUC)-1, Her-2, carcinoembryonic antigen (CEA), and 
survivin [56-58].  
4.1 The EGF receptor family 
The epidermal growth factor receptor (EGFR) family is a group of four related 
transmembrane receptor tyrosine kinases that have been implicated in the development of a 
multiple solid malignancies and have subsequently been targeted in a variety of novel 
therapeutics [59]. The EGFR family consists of HER-1 (also known as ERBB1), HER-2 
(ERBB2), HER-3 (ERBB3) and HER-4 (ERBB4). These receptors bind 13 different ligands and 
form a number of different dimers between the family members. Ligand binding and 
dimerazation initiates various intracellular signaling pathways that affect numerous cellular 
processes involved in cell survival and proliferation. The oncogenic effects of the EGFR 
proteins result from amplification, over expression or mutation [60]. Refer to Fig. 1. 
4.2 HER-1, HER-3, HER-4 
HER-1 is a non-tissue specific peptide that has been implicated in the oncogenesis of 
multiple malignancies including breast, colorectal, pancreatic adenocarcinoma, brain glioma 
multiforme and non-small cell lung cancer [60]. The Food and Drug Administration (FDA) 
recently approved the use of a novel HER-1 directed tyrosine kinase inhibitor, erlotinab, in 
conjunction with other established medications for the treatment of advanced pancreatic 
and non-small cell lung cancers [61]. In addition, cetuximab is an anti-HER-1 monoclonal 
antibody that has been approved to treat patients with advanced colorectal cancer [62]. 
Although no anti-tumor vaccines have been formulated that are directed against HER-1, it is 
a feasible possibility to target this protein in order to develop an anti-HER-1 T cell response.  
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Fig. 1. The EGF receptor family. 
HER-3 has a more ambiguous role in tumorigenesis compared to the other members of the 
EGFR family. It is frequently expressed in breast, ovarian and lung cancers [62-64]. The role 
of HER-4 in relationship to tumor development is also not clear. HER-4 mutations have 
recently been shown to augment proliferation and cell survival in melanomas. Agents that 
target HER-4 may be found to be effective against melanoma and other cancers [60].  
4.3 HER-2 
The HER-2 protein is a well established target of immunotherapy in breast cancer. The 
proto-oncogene HER-2 is found on chromosome 17q and encodes a transmembrane tyrosine 
kinase growth factor receptor. HER-2 over expression occurs in ovarian, pancreatic, gastric, 
lung and head/neck cancers [65-68]. Twenty to thirty percent of breast cancers have been 
found to amplify the HER-2 gene or overexpress the HER-2 protein, which portends a 
poorer prognosis and higher risk of recurrence in patients with both invasive and in situ 
disease [69].  
HER-2 represents an ideal target for antigen-specific vaccines used to treat breast cancer. 
Over expression of this protein is immunogenic as it induces a T cell immune response 
causing HER-2 specific antibodies to be present in the serum of breast cancer patient [70]. 
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The feasibility of HER-2 targeted vaccines has been demonstrated in animal models [71]. In 
addition, a number of phase I and II trials using HER-2 based vaccines of all types have been 
performed in patients with high risk breast cancer. The vaccines in all of these studies were 
well tolerated and caused minimal toxicity [18].  
5. Development of dendritic cell vaccines for the treatment and prevention of 
cancer 
The concept of producing a vaccine aimed at specific breast cancer antigens is theoretically 
straightforward although the details and execution are obviously complex to carry out. 
There are several different vaccine approaches under investigation for the treatment of early 
and late stage breast cancer (dendritic cells, whole tumor cells, peptide-based and viral-
based) [72, 73]. Breast cancer vaccines utilizing all of these different strategies are in various 
stages of development [18, 38, 72-74]. A comprehensive review of the published data on all 
breast cancer vaccines is beyond the scope of this chapter.  
The advent of dendritic cell (DC) vaccines, propelled by the ability to culture human DC 
cells, has provided promise for a novel vaccine strategies [75]. Despite preclinical evidence 
and high expectations for the potential effectiveness of DC-based cancer vaccines, initial 
results of clinical trials were somewhat disappointing with discordant tumor response rates 
[43, 76, 77]. However, continued interest in therapeutic possibilities of DC vaccines has led 
to recent successes and promising data in breast and other cancers. The efficacy of DC 
vaccines continues to improve as efforts have been made to optimize DC vaccines and 
circumvent tumor escape mechanisms.  
5.1 Dendritic cells 
DC vaccines represent one of a number of strategies for vaccinating patients against tumor-
associated antigens. DCs are the most powerful of the APCs and are the primary means by 
which naïve T cells become immunized to specific antigens. DCs are unique in their ability 
to activate both the innate and adaptive immune systems. Immature DCs arise from 
progenitors in the bone marrow and then enter the blood stream and circulate throughout 
the peripheral tissues where they are exposed to foreign antigens. After capturing antigens, 
DCs undergo a maturation process that ultimately guides their travel to secondary 
lymphoid tissues. Once in the regional lymph nodes, the DCs process the captured antigen 
and then display the antigen as a peptide on their MHC molecules. DCs present the 
peptides to naïve T cells resulting in T lymphocyte expansion and differentiation.  
In addition to T cell stimulation, contact with DCs causes activation of B lymphocytes which 
leads them to differentiate into plasma cells that subsequently release antibodies targeted 
against the initial pathogen. After antigen exposure, DCs also release cytokines which can 
activate the cells of the innate immune system, including eosinophils, macrophages, and NK 
cells. In this way, DCs are capable of activating both the innate and adaptive immunity and 
are central to the communication between the two immune systems [36, 78-80].  
5.2 Production and adminstration of DC vaccines 
No standard protocol exists for the production of DC vaccines, but there are some general 
components that are often involved. First, the DCs are collected from the patient via 
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leukapheresis and then activated ex vivo with the specific tumor antigen and human 
granulocyte-macrophage colony-stimulating factor (GM-CSF). The activated DCs are then 
reintroduced to the patient in order to stimulate a T cell response. We have developed a DC 
vaccine targeting HER-2 and used to treat patients with DCIS. The production process will 
be briefly described. 
First, peripheral blood monocytes are obtained by leukapheresis followed by elutriation 
under good clinical practice conditions. Monocytes are then cultured overnight in 
monocyte-macrophage serum-free medium GM-CSF and interleukin (IL)-4. Immature DCs 
are next pulsed with HER-2 MHC II binding peptides, extracellular and intracellular 
domain peptides for 12 hours. In order to potentiate the benefits of signaling infectious non-
self at the time of vaccine administration, we then sequentially culture the cells with 
interferon-gamma (IFN-┛) and bacterial lipopolysaccharcharide (LPS), a TLR agonist, prior 
to pulsing with MHC class I peptides. As mentioned previously, TLR stimulation leads to 
cytokine release and DC maturation. This activation strategy assures that the DC are able to 
robustly secrete IL-12 which maximizes their ability to produce IFN-┛ and a functional T cell 
response [55].  
The major technical disadvantage to the use of DC vaccines relates to the ex-vivo nature of 
their generation. A number of obstacles must be dealt with in order to make the process 
successful and efficient [36, 81]. Most importantly, the production of DC must be made 
individually for each patient. The process is dependent on access to leukapheresis facilities 
at the treatment center. Leukapheresis is complex procedure that does not always generate 
consistent results. The procedure is associated with minimal patient morbidity including, 
brief electrolyte imbalances, minimal risk of infection and vascular injury. Another 
important consideration in the production of DC vaccines is the financial burden of 
manufacturing and administering such an individualized treatment. Sipuleucel-T, the only 
cancer vaccine that is currently approved by the FDA, is priced at $31,000 and is typically 
given three times, making a complete treatment cost $93,000. This is one of the most 
expensive cancer therapies ever approved [77, 82].  
We advocate injecting the vaccines directly into distal lymph nodes. It has been shown 
that only a proportion of peripherally administered DCs migrate to regional lymph nodes 
[83]. Using ultrasound guidance to inject the cultured DCs directly into distal lymph 
nodes assures that a predetermined and defined quantity of antigen-loaded DC cells are 
delivered to the site of T-cell sensitization, thus allowing the vaccine to activate an 
adaptive immune response. This method also synchronizes peak IL-2 secretion to occur 
when the DCs are close to T cells. Vaccinating patients prior to surgical resection also 
allows us to have the opportunity to review the histopathological effects of vaccination on 
the tumor cells [36].  
In April 2010, the FDA approved the first cancer vaccine. This individualized DC vaccine, 
Sipuleucel-T (Provenge; Dendreon Corp.), is approved for use in men with metastatic 
castration-resistant prostate cancer. Similar to other DC vaccines, the production of 
Sipuleucel-T begins with leukaphoresis and the isolation of peripheral blood mononuclear 
cells. The DCs are then activated by exposure to a recombinant fusion protein (prostatic acid 
phosphatase and GM-CSF). The treated cells are re-infused into the patient. This process is 
repeated every two weeks for a total of three treatments [84].  
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The results from initial trials reported a 41 % relative reduction in the risk of death and a 
trend toward increased survival in the men treated with Sipuleucel-T compared to the men 
in the placebo group [85, 86]. The IMPACT study, a double-blind, placebo-controlled, 
multicenter trial involving 512 men with metastatic castration-resistant prostate cancer, was 
designed with overall survival as the primary endpoint. Of note, these men were either 
asymptomatic or minimally symptomatic, representing a patient population that is at an 
earlier stage and therefore more likely to be amenable to immunotherapy. Compared with 
the placebo arm, patients in the Sipuleucel-T arm achieved a 22% relative reduction in the 
risk of death. This represented a 4.1 month increase in median overall survival between the 
placebo and Sipuleucel-T arms. There was no significant difference achieved in the prostate-
specific antigen response or time to progression between the two arms. Sipuleucel-T was 
well tolerated [84]. 
6. DC vaccination in breast cancer 
Successful reduction of HER-2 over expressing tumors requires activation of both the innate 
and adaptive immune responses [87]. As described, DCs are unique in their ability to elicit 
responses from tumor-specific effector and memory T cells. Numerous strategies exist that 
aim to introduce tumor antigens into DCs in order to generate vaccines (loading individual 
tumor peptides, transfer of tumor-specific DNA or RNA through lipofection or viral vectors, 
whole tumor cell fusion). An early DC vaccine strategy for breast cancer involved the 
production of DC/tumor cell fusion vaccines. Avigen et al conducted a trial in which 16 
patients with metastatic breast cancer were injected with a fusion vaccine using tumor cells 
obtained from a biopsy and DCs acquired from leukapheresis [88]. Three patients had a 
significant clinical response. Unfortunately the efficacy of fusion cell generation is less than 
45% and multiple patients were not able to receive the full course of vaccines due to limited 
yield.  
In 2007, Park et al published data from a phase I study in which they treated 18 metastatic 
breast cancer patients with Lapuleucel-T (Dendreon Corp), a vaccine produced in a similar 
fashion as sipuleucel-T, although a HER-2 fusion protein is used [89]. The study was 
designed to evaluate the safety and immunologic activity of the novel agent. The therapy 
was well tolerated. Significant immune responses were stimulated (as measured by 
lymphocyte proliferation and IFN-┛ enzyme-linked immunospot assays). The therapy was 
also associated with tumor response and extended disease stabilization. Further trials are 
warranted to determine the efficacy in patients with earlier stage disease and in combination 
with other anti-HER-2 therapies.  
Another DC vaccine approach that is being explored is Adevexin (Introgen Therapuetics), 
made form leukapheresed APCs that are transfected with a replication-impaired adenoviral 
vector that brings the p53 gene under control of a cytomegalovirus promoter [90]. This 
vaccine is not specifically anti-HER-2, but instead works under the theory that p53 
restoration can be used to treat cancer. This vaccine triggers p53-specific T-cell responses 
against cancer cells with mutant p53 and has proven to be safe and synergistically effective 
in a number of tumor types.  
Currently other anti-HER-2 DC vaccines trials are recruiting patients and results of these 
trials are pending [74]. We are conducting a clinical trial with a novel DC vaccine designed 
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to treat DCIS patients with lesions that overexpress HER-2. No other DC-based vaccines 
have been designed specifically to treat HER-2 expressing DCIS tumors. We anticipate a 
significant reduction in disease burden in our patients after a complete vaccine course. We 
hope that this vaccine will also be preventative in terms of both disease recurrence and rate 
of transformation into invasive breast cancer.  
Our strategy of vaccine production utilizes both MHC I and II peptides as well as ex vivo 
activation with IFN-┛ and LPS to yield polarized DC cells that induce a unique set of soluble 
factors including high levels of IL-12 and Th1 chemokines not elicited through traditional 
vaccines methods. This innovative DC vaccine strategy called Immune Conditioning by 
Activated Innate Transfer (ICAIT) uses monocyte-derived DCs that are activated with and a 
special clinical-grade TLR 4 ligand, LPS and IFN-┛ (ICAIT-DC). This unique DC activation 
method gives the DCs qualities that are not found in the so-called “gold-standard” DCs 
used in prior vaccine trials. The “gold standard” DC vaccines, activated with TNF, IL-6, 
PGE2, IL-1┚, have the potential to simulate aseptic inflammation [91]. In contrast, ICAIT-
DCs produce high levels of factors that specifically enhance aspects of anti-tumor immunity 
such as NK cells which augment tumor rejection, and TNF and IL-12 which are anti-
angiogenic [55, 92]. ICAIT-DCs also have the distinct ability to influence the quality of 
sensitized T cells and can condition T cells for recognition of HER-2 expressing tumors. 
Lastly, ICAIT-DCs posses a killer function that enables them to lyse breast cancer cells.  
Our DC vaccine is unique in its design against DCIS rather than invasive breast cancer. Our 
first neoadjuvant trial involved treating patients with HER-2 expressing DCIS tumors. The 
patients were treated with a course of four weekly intranodal injections of ICAIT-DCs that 
had been pulsed with HER-2 derived proteins. This approach yielded promising results that 
have positive implications for the treatment and prevention of high risk breast cancers. 
Specifically, 85% of ICAIT-treated patients developed immune responses to at least one of 
the HER-2 peptides. Eleven of the 22 patients with residual DCIS treated with the vaccine in 
our initial studies showed loss of HER-2 expression and tumor regression. The immunized 
patients developed a specific immune response against the HER-derived peptides and 
presented high levels of CD4+ and CD8+ T lymphocytes. These results have potential 
positive implications not only for prognosis but also in terms of breast-conserving surgery 
[55]. Five of the 27 patients had no evidence of remaining disease. The vaccination was most 
effective in patients with hormone-independent DCIS as 40% of ER negative HER-2 positive 
patients had no residual disease whereas only 5% of ER positive HER-2 positive had no 
residual disease. The vaccine appeared to alter the phenotype of the remaining DCIS in the 
patients that were found to have residual disease. The rate of change to a different post-
vaccination phenotype was significantly different between the ER positive and ER negative 
patients. 43.8% of the patients that were initially ER positive and HER-2 positive phenotype 
converted to ER positive and HER-2 negative phenotype. In comparison, 50% of the patients 
that initially had tumors that were ER negative and HER-2 positive changed to the ER 
negative and HER-2 negative phenotype. These results supported the safety and efficacy of 
the DC based HER-2 vaccine. The vaccine induced a decline or eradication of HER-2 
expression (work not yet published).  
7. Future direction and prevention  
There are a number of molecules that have been discovered to be present in breast 
carcinomas that have not yet been exploited to their fullest potential. The future directions 
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for the development of breast cancer vaccines should focus not only on targeting molecules 
that are specific tumor related antigens, but also to the downstream signaling pathways 
involved in tumorigenesis. For example, recent work has elucidated the role of survivin 
(Figure 1), a protein in the anti-apoptotic family. Blocking the expression of survivin, was 
found to have a direct role in the initiation of apoptosis of breast cancer cells [93]. Up-
regulation of survivin is also directly linked to HER-2 over expression [94]. A novel anti-
survivin based therapy in combination with an anti-HER-2 DC vaccine is an exciting 
possibility to treat and possibly prevent breast cancers.  
Another promising possibility is to develop immune responses against other HER family 
members including HER-1 and HER-3. HER-3 has no ligand binding sites but intracellular 
signaling moieties and can partner with HER-2 and HER-1. HER-3 signaling may lead to 
HER-2 resistance thus developing vaccines against these targets may supplement HER-2 
vaccines to make them better preventive agents eliminating vaccine escapes.  
MUC-1(Figure 1), an epithelial glycoprotein that is over expressed in may breast cancers, is 
another molecule that has yet to be fully exploited as an anti-cancer drug target. This 
molecule has been implicated in tumor invasion and metastases [95]. MUC-1 pulsed DC 
based vaccine trials for patients with pancreatic and biliary carcinomas are currently 
underway and the clinical efficacy of these vaccines is not known at this time [96]. MUC-1 is 
another molecule that could potentially used to target breast cancers.  
There is immeasurable potential for vaccine therapy to be used in immunocompetent 
patients with minimal disease to prevent disease progression and recurrence. Even more 
exciting is the potential to treat patients with no disease at all. Forty percent of the 
participants in our recent vaccine trial converted from ER positive HER-2 positive to ER 
positve HER-2 negative suggesting that HER-2 vaccines can direct or steer tumors  to more 
favorable phenotypes. The ultimate goal is therefore to produce a vaccine that could prevent 
breast cancer formation altogether. The development of successful breast cancer prevention 
would be applicable to other solid tumor malignancies such as colorectal, head and neck 
cancer, lung cancer, gastric cancer and other GI malignancies. 
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